Parkinson’s Disease

Project open for codevelopment


Therapeutic area: CNS, neurodegenerative disorders

Disease: Parkinson’s Disease

Monogenic inroad: Alpha Synuclein (SNCA) and LRRK2 (G2019S)

Cellular Model: Patient-derived cell lines

Project Origin: University of Luxembourg, Prof. Rejko Krüger

Medical need: Parkinson’s disease (PD) is the second most common neurodegenerative disorder currently affecting between 7-10 million people worldwide. The annual cost of PD in Europe is in excess of 14 billion euros (Olesen et al, Eur J Neurol, 2012). SNCA mutations are associated with autosomal dominant forms of PD. SNCA is deemed as one of the major causative genes in different neurodegenerative disorders.

GoalThe program aims for development and implementation of  physiologically highly-relevant cellular disease models (assays). Assay development is based on human differentiated induced pluripotent stem cells (iPSC), and tailored AI-based image analysis methodologies. The assays are rendered applicable for HTS-HCS, and will be used for the development of disease modifying treatments.

Development stage: The assays have been validated through a set of compounds and are currently automated.

Want to know more about this project ?